Cargando…

Who stop telemonitoring disease activity and who adhere: a prospective cohort study of patients with inflammatory arthritis

BACKGROUND: The use of frequent electronic patient reported outcome measures (ePRO’s) enables monitoring disease activity at a distance (telemonitoring) in patients with inflammatory arthritis. However, telemonitoring studies report declining long-term adherence to reporting ePRO’s, which may oppose...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiegel, J., Seppen, B. F., Nurmohamed, M. T., Bos, W. H., ter Wee, M. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708135/
https://www.ncbi.nlm.nih.gov/pubmed/36447263
http://dx.doi.org/10.1186/s41927-022-00303-w
_version_ 1784840855202299904
author Wiegel, J.
Seppen, B. F.
Nurmohamed, M. T.
Bos, W. H.
ter Wee, M. M.
author_facet Wiegel, J.
Seppen, B. F.
Nurmohamed, M. T.
Bos, W. H.
ter Wee, M. M.
author_sort Wiegel, J.
collection PubMed
description BACKGROUND: The use of frequent electronic patient reported outcome measures (ePRO’s) enables monitoring disease activity at a distance (telemonitoring) in patients with inflammatory arthritis. However, telemonitoring studies report declining long-term adherence to reporting ePRO’s, which may oppose the benefits of telemonitoring. Therefore, the objective was to investigate what factors are associated with (non-)adherence to telemonitoring with a weekly ePRO in patients with inflammatory arthritis (IA). METHODS: We performed a prospective cohort study in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) at Reade Amsterdam, The Netherlands. Patients telemonitored their disease activity weekly for 6 months with a modified Multidimensional Health Assessment Questionnaire completed in a smartphone application. The primary outcome was time to dropout, defined as ≥ 4 weeks of consecutively nonresponse. Based on literature and through expert meetings, a predefined set of 13 baseline factors were selected to assess the association with time to dropout through a multivariable Cox-regression analysis. RESULTS: A total of 220 consecutive patients were included (mean age 54, SD 12; 55% females; 99 RA, 81 PsA, and 40 AS). A total of 141 patients (64%) dropped out, with a median time to dropout of 17 weeks (IQR 9–26). Women had a significant higher chance to dropout over 6 months compared to men (HR 1.58, 95% CI 1.06–2.36). CONCLUSION: In the set of investigated factors, women stopped reporting the weekly ePRO sooner than men. Future focus group discussions will be performed to investigate the reasons for dropout, and in specific why women dropped out sooner. Trial registration This trials was prospectively registered at www.trialregister.nl (NL8414). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41927-022-00303-w.
format Online
Article
Text
id pubmed-9708135
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97081352022-11-30 Who stop telemonitoring disease activity and who adhere: a prospective cohort study of patients with inflammatory arthritis Wiegel, J. Seppen, B. F. Nurmohamed, M. T. Bos, W. H. ter Wee, M. M. BMC Rheumatol Research BACKGROUND: The use of frequent electronic patient reported outcome measures (ePRO’s) enables monitoring disease activity at a distance (telemonitoring) in patients with inflammatory arthritis. However, telemonitoring studies report declining long-term adherence to reporting ePRO’s, which may oppose the benefits of telemonitoring. Therefore, the objective was to investigate what factors are associated with (non-)adherence to telemonitoring with a weekly ePRO in patients with inflammatory arthritis (IA). METHODS: We performed a prospective cohort study in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) at Reade Amsterdam, The Netherlands. Patients telemonitored their disease activity weekly for 6 months with a modified Multidimensional Health Assessment Questionnaire completed in a smartphone application. The primary outcome was time to dropout, defined as ≥ 4 weeks of consecutively nonresponse. Based on literature and through expert meetings, a predefined set of 13 baseline factors were selected to assess the association with time to dropout through a multivariable Cox-regression analysis. RESULTS: A total of 220 consecutive patients were included (mean age 54, SD 12; 55% females; 99 RA, 81 PsA, and 40 AS). A total of 141 patients (64%) dropped out, with a median time to dropout of 17 weeks (IQR 9–26). Women had a significant higher chance to dropout over 6 months compared to men (HR 1.58, 95% CI 1.06–2.36). CONCLUSION: In the set of investigated factors, women stopped reporting the weekly ePRO sooner than men. Future focus group discussions will be performed to investigate the reasons for dropout, and in specific why women dropped out sooner. Trial registration This trials was prospectively registered at www.trialregister.nl (NL8414). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41927-022-00303-w. BioMed Central 2022-11-30 /pmc/articles/PMC9708135/ /pubmed/36447263 http://dx.doi.org/10.1186/s41927-022-00303-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wiegel, J.
Seppen, B. F.
Nurmohamed, M. T.
Bos, W. H.
ter Wee, M. M.
Who stop telemonitoring disease activity and who adhere: a prospective cohort study of patients with inflammatory arthritis
title Who stop telemonitoring disease activity and who adhere: a prospective cohort study of patients with inflammatory arthritis
title_full Who stop telemonitoring disease activity and who adhere: a prospective cohort study of patients with inflammatory arthritis
title_fullStr Who stop telemonitoring disease activity and who adhere: a prospective cohort study of patients with inflammatory arthritis
title_full_unstemmed Who stop telemonitoring disease activity and who adhere: a prospective cohort study of patients with inflammatory arthritis
title_short Who stop telemonitoring disease activity and who adhere: a prospective cohort study of patients with inflammatory arthritis
title_sort who stop telemonitoring disease activity and who adhere: a prospective cohort study of patients with inflammatory arthritis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708135/
https://www.ncbi.nlm.nih.gov/pubmed/36447263
http://dx.doi.org/10.1186/s41927-022-00303-w
work_keys_str_mv AT wiegelj whostoptelemonitoringdiseaseactivityandwhoadhereaprospectivecohortstudyofpatientswithinflammatoryarthritis
AT seppenbf whostoptelemonitoringdiseaseactivityandwhoadhereaprospectivecohortstudyofpatientswithinflammatoryarthritis
AT nurmohamedmt whostoptelemonitoringdiseaseactivityandwhoadhereaprospectivecohortstudyofpatientswithinflammatoryarthritis
AT boswh whostoptelemonitoringdiseaseactivityandwhoadhereaprospectivecohortstudyofpatientswithinflammatoryarthritis
AT terweemm whostoptelemonitoringdiseaseactivityandwhoadhereaprospectivecohortstudyofpatientswithinflammatoryarthritis